Where does MedImmune Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), MedImmune Limited ranks #1,293 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does MedImmune Limited hold?

MedImmune Limited holds 327 US utility patents granted between 2015 and 2025, spanning 28 technology areas.

What is MedImmune Limited's Innovation Score?

MedImmune Limited has an Innovation Score of 54.1 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does MedImmune Limited focus on?

MedImmune Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 283 patents, ranking #43 of 6,058 assignees active in that subclass. Grants appear in 28 CPC subclasses total.

Is MedImmune Limited's patent grant rate increasing or decreasing?

MedImmune Limited's recent grant velocity is -10% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for MedImmune Limited's patents?

MedImmune Limited's patents average 17.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the MedImmune Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

MedImmune Limited

USPTO PatentsView assignee record - 327 granted patents across 28 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medimmune ranks #1,293 of 49,997 tracked US assignees by granted-patent volume, with 327 patents across 28 technology areas.

#1,293
of 49,997 US assignees by volume: Top 8%
by Innovation Score (54.1/100): 17.4
avg claims per patent: -10%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1293 · Foreign Corporation #1,293 · 327 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 327 grants
TOP-DECILE #1,293/49,997
PHOTO-FINISH Alpha and Omega…
CPC-FOCUS A61P · 28 areas
INNOV-PAR 54.1/100
CLAIMS-RICH 17.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT -10% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Alpha and Omega Semiconductor, Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medimmune’s 54.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 20.0 pts (37%) Velocity 4.9 pts (9%) Breadth 18.7 pts (35%) Claim depth 10.5 pts (19%)

Qualcomm Incorporated · highest

85
Bragi · near

54
DeRoyal Industries · near

54
MagnaChip Semiconduc… · near

54
MedImmune · this assignee

54
Seiko Instruments · near

54
3D Lighting… · lowest

7

What this shows Medimmune's Innovation Score is 54.1/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medimmune?

Each dot is one of Medimmune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medimmune’s own 17.4 claims/patent is ABOVE the 12.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Medimmune vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medimmune's grants concentrate

MedImmune Limited is a focused PatentsView assignee: 28 CPC subclasses with 86.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (45 grants) versus a trough of 18 in 2024. By volume, Medimmune sits between Yissum Research Development Company OF THE Hebrew University OF Jerusalem Ltd. and Klemm + Sohn GMBH & Co. KG.

Medimmune's three-year grant acceleration

From 2019–2021 to 2022–2024, MedImmune Limited moved from 105 to 77 grants (0.73x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,038. See the growth leaderboard.

Yissum Research D…

329
Safran

328
Alpha and Omega S…

327
Brother Industries

327
University of Hou…

327
Medimmune ◀

327
Bayer Pharma Akti…

326
Hangzhou Hikvisio…

326
Klemm + Sohn & KG

326

What this shows MedImmune holds 327 patents at rank #1,293, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near MedImmune

By rank, the assignees closest to #1,293 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in MedImmune's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for MedImmune, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), MedImmune ranks #43 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (54 here).

Seiko Instruments Inc. 54 MagnaChip Semiconductor, Ltd. 54 Bragi GmbH 54 DeRoyal Industries, Inc. 54

Similar claim depth

Nearest assignees by average claims per patent (17.4 here).

Unisys Corporation 17.4 avg Chevron U.S.A. Inc. 17.4 avg NewSouth Innovations Pty Limited 17.4 avg Elekta AB (publ) 17.4 avg

Medimmune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

MedImmune Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	27	8.3%
2016	31	9.5%
2017	29	8.9%
2018	45	13.8%
2019	33	10.1%
2020	44	13.5%
2021	28	8.6%
2022	26	8.0%
2023	33	10.1%
2024	18	5.5%
2025partial year	13	4.0%

Which technologies does MedImmune Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 283

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 280

C07K - Peptides 264

C07D - Heterocyclic Compounds 57

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 52

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 47

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 16

Y02A - Technologies FOR Adaptation TO Climate Change 16

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 13

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 8

C12Y - Enzymes 6

C07C - Acyclic OR Carbocyclic Compounds 6

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 5

B01D - Separation 5

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 5

Top 15 of 28 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

MedImmune Limited's patent record in context - here's where to go next.

MedImmune Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 86.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,293 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare MedImmune Limited against Yissum Research Development Company OF THE Hebrew University OF Jerusalem Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 54.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.